Elizabeth Yeu Lin - 15 Dec 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Chief Medical Officer
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 15 Dec 2025
Net transactions value: -$165,201
Form type: 4
Filing time: 17 Dec 2025, 16:07:14 UTC
Previous filing: 20 Jun 2025
Next filing: 09 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lin Elizabeth Yeu	Chief Medical Officer	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE	/s/ Scott Sieckert, Attorney-in-Fact	17 Dec 2025	0001842190

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TARS	Common Stock	Options Exercise		+6,819	+40%		24,019	15 Dec 2025	Direct	F1, F2
transaction	TARS	Common Stock	Sale	$165,201	-2,078	-8.7%	$79.50	21,941	16 Dec 2025	Direct	F3
holding	TARS	Common Stock						6,360	15 Dec 2025	By Spouse's Roth IRA	F2
holding	TARS	Common Stock						12,040	15 Dec 2025	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Restricted Stock Units	Options Exercise	$0	-6,819	-25%	$0.000000	20,459	15 Dec 2025	Common Stock	6,819		Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2	Since the date of the Reporting Person's last report, 9,506 shares previously owned by the Reporting Person's Spouse's Roth IRA were transferred to the Reporting Person's self-directed IRA and are now directly owned.
F3	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4	Each RSU represents a contingent right to receive one share of the Company's common stock.
F5	RSUs granted on November 4, 2024 in connection with the Reporting Person's appointment as Chief Medical Officer. 25% of the RSUs will vest on December 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.